Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.

Susanne Crocamo Ventilari da CostaRenata BinatoBruno de PaulaGiselle VignalLídia MagalhãesRoberta SarmentoMaria Theresa AcciolyIsabele SmallSandra GioiaPedro MarounPamela MoutinhoVivianne A R FreitasKaruline CateinEliana Abdelhay

Published in: Therapeutic advances in medical oncology (2019)

The addition of ZOL as a repositioning drug in neoadjuvant treatment was an effective and well-tolerated therapy. This drug combination might overcome endocrine and anti-HER2 resistance. The higher pCR rates in the HR-positive subgroup deserve further translational investigation.

Keyphrases

positive breast cancer
rectal cancer
locally advanced
lymph node
phase iii
clinical trial
study protocol
adverse drug
drug induced
randomized controlled trial
squamous cell carcinoma
radiation therapy
emergency department
open label
cell therapy
bone marrow
smoking cessation